Amgen Stock Jumps to Near-Yearly High After Strong Q2 Earnings

Amgen stock prices have reached near-record highs after the biotechnology company reported its Q2 2026 earnings, exceeding analyst expectations.

The company's adjusted EPS came in at $6.29, beating the consensus estimate of $5.62 by $0.67, while revenue also exceeded projections at $10.05 billion, a year-over-year increase of 9.5% from Q2 2025.

Amgen's market capitalization stands at approximately $223.98 billion, with its current stock price hovering around $414.30 on August 11, 2026, according to MarketBeat data.

The positive earnings report and increased revenue guidance for FY 2026 have contributed to the company's rising stock prices, which now sit above the average target of $371.68 set by analysts.